. Sirt1 activation dampens the class-switched/hypermutated T-independent antibody response in a B cell-intrinsic fashion. The NBSGW/B mice were injected (i.p.) with SRT1720 (0.3 mg in 200 ml PBS, n = 4) or PBS only (Nil, n = 4) once every two days. These mice were then i.p. injected with NP0.5-LPS (50 g in 200 ml PBS) at days 0, 2, 4 and 6, and sacrificed 7 d after the last NP0.5-LPS injection. (A) Serum titers of total and NP4-binding IgM, IgG3 and IgG2b as measured by ELISA (means ± SEM). (B and C) Viable (7-AAD − ) spleen CD19 + B cells (B) as well as CSR and plasma cell differentiation (C) as analyzed by flow cytometry. Data are from mice representative of each group. (D) qRT-PCR analysis of gene expression, as indicated. Values were normalized to the expression of Gapdh and depicted as ratios to expression in nil-treated mice (means ± SEM of values from 4 mice, each consisting of triplicates). (E) Somatic point-mutations in the V186.2 region of V186.2DJH-C2b and V186.2DJH-C3 cDNA clones from three pairs of mice treated with nil or SRT1720. The frequency of mutations in different NBSGW/B mice were compared by enumerating the point-mutations in the V186.2 segment of three "comparable" V186.2DJH-Cg3 and V186.2DJH-Cg2b clone pairs (each pair consisting of a mouse treated with nil and one with SRT1720). Comparable pairs were defined as B cell clones expressing V186.2DJH-Cg3 or V186.2DJH-Cg2b with IgH CDR3s being identical in length (7 to 12 amino acids), identical in the first two amino acids and identical in the last three or four amino acids. One of the three V186.2DJH-Cg3 clone pairs was in fact identical in the whole IgH CDR3 sequence (ARGYFDY). Each dot represents an individual sequence. The number of sequences analyzed from each clone is indicated below the dot plots. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-tailed Student's t-test. promoter, as detected by ChIP assays using anti-Dnmt3l,followed by qPCR. (E and F) C57BL/6 mouse B cells were cultured in glucose-free medium supplied with 0, 5.0, or 10 mM of glucose and stimulated with LPS plus IL-4 for 72 hours (E). DNA methylation of the Irf4 promoter, as analyzed by MeDIP-qPCR (F). Data in A to F are means ± SEM of three biological independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant, paired two-tailed Student's t-test. Fig. 4I , in Aicda cre Sirt1 fl/fl B cells stimulated by LPS or CD154 plus IL-4, increased NF-B p65 acetylation resulted in increased recruitment of p65-Ac to the Aicda promoter (by up to 8.7 folds, as shown by ChIP with an anti-p65-Ac mAb), further increasing Aicda expression. p65 acetylation also resulted in some recruitment of p65-Ac to the Prdm1 promoter (by less than two folds). This was not, however, associated with upregulated Prdm1 expression (Fig. 2M) . This was possibly due to decreased Irf4, which positively regulates Prdm1 expression by targeting Prdm1 regulatory region (Sciammas et al., Immunity, 25:225-236 , 2006) . Irf4 expression is negatively controlled by DNA methylation of its promoter (Ortmann et al., Nucleic Acids Res. 33:6895-6905,2005) , which, as suggested by our experiments, can be effected by the DNA methytransferase Dnmt3l (fig. S6) . Sirt1 can downregulate the expression of Dnmt3l by histone deacetylation of the Dnmt3l promoter (Heo et al., Cell Rep., 18:1930 -1945 , 2017 . Dnmt3l can be recruited to the promoter of Irf4 and modulate Irf4 DNA methylation and expression. B cell-specific Sirt1 deletion or metabolic Sirt1 inactivation by higher glucose concentration resulting inincreased Dnmt3l expression and Dnmt3l recruitment to the Irf4 promoter, which resulted in increased DNA methylation in the Irf4 promoter that led to reduced Irf4 expression ( fig. S6 ). This would have nullified a potential Prdm1 upregulation brought about by increased p65 acetylation and p65-Ac recruitment to the Prdm1 promoter, thereby leading to virtually unchanged Prdm1 expression in B cells in which Sirt1 was downregulated, deleted or Sirt1 metabolically inactivated. 
